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Abstract: Tumor suppressor p53 is widely known as ‘the guardian of the genome’ due to its 
ability to prevent the emergence of transformed cells by the induction of cell cycle arrest 
and apoptosis. However, recent studies indicate that p53 is also a direct transcriptional 
target of type I interferons (IFNs) and thus, it is activated by these cytokines upon viral 
infection. p53 has been shown to contribute to virus-induced apoptosis, therefore dampening 
the ability of a wide range of viruses to replicate and spread. Interestingly, recent studies 
also indicate that several IFN-inducible genes such as interferon regulatory factor 9 (IRF9), 
IRF5, IFN-stimulated gene 15 (ISG15) and toll-like receptor 3 (TLR3) are in fact, p53 direct 
transcriptional targets. These findings indicate that p53 may play a key role in antiviral 
innate immunity by both inducing apoptosis in response to viral infection, and enforcing the 
type I IFN response, and provide a new insight into the evolutionary reasons why many 
viruses encode p53 antagonistic proteins.  
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1. Introduction 
An important host defense mechanism against virus infection, the type I IFNs, are rapidly induced 
to activate an antiviral state in infected and neighboring uninfected cells. Type I IFNs bind to the type I 
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IFN receptor formed by IFNAR1 and IFNAR2 subunits [1,2] and trigger the activation of the 
canonical Jak/signal transducer and activator of transcription (STAT) signaling pathway and the trans-
activation of antiviral genes, through a mechanism that depends to a great extent on STAT1, STAT2 
and IRF9 [3]. These three transcription factors form the trimeric IFN-stimulated gene factor 3 (ISGF3) 
complex, which is relocated to the nucleus where it binds to the IFN-stimulated response elements 
(ISREs) in promoters of target genes to activate their transcription. Since type I IFNs stimulate p53 
expression and virus infection activates p53 [4], this tumor suppressor has been recently included as a 
new component of the cellular antiviral defense mechanisms. Studies by us and others in recent years 
indicate that p53 is in fact, a key player in innate antiviral immunity by both enforcing the type I IFN 
response upon viral infection, and inducing apoptosis in infected cells [5-9]. Both actions coordinated 
by this tumor suppressor gene, help to thwart the replication of a wide variety of viruses both in vitro 
and in vivo [5-9]. In this review we try to provide a summary of the recent findings that involve p53 in 
antiviral immunity and that presumably, may help to explain not only why this protein is conserved in 
invertebrate organisms which do not undergo cancer-related diseases, but also, why this protein is so 
frequently targeted by viral proteins. 
2. Regulation of p53 functions 
The potent activity of p53 as inducer of cellular apoptosis and cell cycle arrest demands tight 
control of its function. In normal cells the level of p53 protein is low due to its short half-life [10] 
regulated mainly by murine double minute 2 (Mdm2) protein. Mdm2 inhibits p53 transactivation and 
prompts p53 for proteasomal degradation by promoting its ubiquitylation [11,12]. In contrast, p53 is 
stabilized and activated when, in response to oncogene expression, another tumor suppressor gene, 
namely ARF, binds to Mdm2 and blocks its ability to inhibit p53 function [13]. Similarly, the 
nucleolar protein nucleophosmin (NPM) also interacts with Mdm2 and promotes p53 stability and 
function [14]. A recently discovered regulator of p53 activity is the type I IFN pathway. IFN- 
stimulates transcription of the gene encoding p53, through ISRE sites present in its promoter, resulting 
in an early induction of the protein [4], which is later held in time by the action of ARF [15]. 
Importantly, type I IFN seems also to induce p53 protein stabilization through posttranslational 
mechanisms that involve STAT1-dependent transcriptional downregulation of Mdm2 and direct 
protein interaction with p53, at least upon DNA damage [16]. In addition, although acute IFN 
treatment does not cause the activation of p53 [4], chronic treatment of primary cells with IFN-leads 
to p53 phosphorylation at Ser-15 and engagement of p53 downstream genes, indicative of p53 
activation [17]; suggesting that the cellular response to IFN- is time-dependent. Infection with some 
viral agents, such as vesicular stomatitis virus (VSV), Newcastle disease virus (NDV) or herpes 
simplex virus (HSV), probably through the production of interferon, boosts p53 expression, and 
induces the phosphorylation of p53 at Ser-15 by ataxia telangiectasia mutated (ATM) kinase [4]. 
Phosphorylation of p53 in other amino acid residues in response to IFN or virus infection cannot be 
excluded since p53 has been also identified as a substrate for the double-stranded RNA (dsRNA) 
activated protein kinase R (PKR), an IFN-inducible protein kinase which can induce the 
phosphorylation of human p53 at Ser-392 in vitro [18,19], an event that has been proposed to be 
related with the stabilization and activation of p53 [20-22]. In this regard, induction of p53 as a 
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downstream event of tumor necrosis factor alpha (TNF--induced upregulation of PKR has been 
reported, and impaired p53-mediated responses to doxorubicin in PKR KO cells have been described 
[17,18,23].  
3. p53 regulation of apoptosis in the context of viral replication 
p53 induces the expression of a wide number of genes that ultimately impose a state of G1-phase 
cell cycle arrest or apoptosis. Previous studies indicate that the role of p53 in the control of virus 
infection depends at least to some extent on its ability to activate apoptosis through the transactivation 
of p53 classic target genes such as the members of the BH3-only family of proteins PUMA and Noxa 
[4,24]. Interestingly, a recent study also indicates that the type I IFN-inducible protein kinase PKR, is 
a novel p53 target gene, suggesting that PKR could also play a role in p53-dependent induction of 
apoptosis upon viral infection [25].  
An intriguing unresolved question is whether TNF-related cytokines also contribute to p53-
dependent apoptosis in response to viral infection. TNF- is expressed at high levels upon infection 
with several viruses such as influenza A, human immunodeficiency virus (HIV) and Ebola virus 
(EBOV) [26-28]. Expression of TNF-by virus-infected cells induces maturation of resident dendritic 
cells (DCs) through upregulation of the costimulatory molecules CD80 and CD86 [29]. Besides, TNF-
synergizes with type I IFNs and polarizes the adaptive immune response towards a Th1 type 
(cellular immunity) [30,31]. Moreover, recent reports indicate that TNFR-mediated apoptosis of virus-
infected cells may be a key component at the interface between innate and adaptive immunity by 
allowing DCs to cross-present viral antigens to naïve T cells [32]. Specifically, the p53 direct target 
gene TRAIL-R2/DR5/KILLER has been previously shown to promote DC maturation and immune 
enhancement in vivo by activation of caspase 8-dependent apoptosis [33]. Viral antigens produced by 
apoptotic virus-infected cells are then engulfed by DCs which have the ability to present them to CD8+ 
T cells through major histocompatibility complex (MHC) class I [34]. This process may be especially 
important in triggering immunity against viruses that do not naturally infect DCs, and includes not 
only TRAIL-R2/DR5/KILLER but also other p53 direct target genes such as Fas/Apo1/CD95 [35,36]. 
Of note, activation of p53 downstream targets that specifically mediate its proapoptotic activity in 
response to virus infection may be also cell type specific. Thus, although VSV infection induced 
increased apoptosis in a p53 dose-dependent fashion in mouse embryonic fibroblasts (MEFs) [5], 
infection of HCT116 tumor cells retaining wt p53 with VSV, did not elicit an apoptotic response [37]. 
These findings also indicate, that virus-induced p53-dependent apoptosis may require the activity of 
p53 downstream target genes that could be impaired in cancer cell lines such as HCT116.  
p53-dependent apoptosis has been demonstrated as a useful mechanism to control some virus 
infection, as shown for VSV [5,6,38], influenza A virus [7], herpes simplex virus (HSV) [8], or 
poliovirus [9]. In sharp contrast other viruses have evolved mechanisms to use p53 activity in its own 
benefit. Thus, p53 enhances the ability of human cytomegalovirus (HCMV) to replicate in fibroblasts 
[39], increases respiratory syncytial virus (RSV) [40] or adenovirus replication [41] and its absence 
has a detrimental effect in the growth of encephalomyocarditis virus (EMCV) and parainfluenza virus 
[38]. A possible explanation for this striking observation is that, while early apoptosis is probably 
detrimental for replication of some viruses, other viruses may benefit from apoptosis late in the 
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replication cycle in order to improve transmission of newly-formed viral particles to other cells or 
hosts [42].  
The complexity of the p53 response to viral infection is supported by studies addressing the role of 
p53 on dsRNA-induced apoptosis. Although p53 is often considered as a cell death inducer, there are 
also cell types and situations where the presence of p53 prevents cell death by inducing cell cycle 
arrest. Thus, the induction of G1 arrest mediated by p53 in response to dsRNA has been suggested as a 
putative mechanism to delay apoptosis and consequently increase EMCV replication [38]. Moreover, 
p53 functions as a transcription factor are also subverted by some viruses in their own benefit. Thus, 
p53 activates the transcription of the HCMV L44 protein, required for virus replication, and there are 
21 exact matches for the p53 binding site within the virus genome, including sites that could influence 
the expression of proteins involved both in the structure and replication of HCMV [39]. p53 also 
cooperates with E1A to enhance transcription from the major late adenovirus promoter, triggering the 
adenovirus lytic cycle and increasing virus yield [41]. Finally, p53-dependent downregulation of IL-6 
has been suggested to mediate the positive effect of p53 on RSV replication. However, the decrease in 
the p53 levels induced by RSV to delay apoptosis paradoxically enhances the host inflammation 
response that hampers virus replication [40]. 
4. p53 direct target genes in the type I interferon pathway 
Takaoka and colleagues [4] identified p53 as a type I IFN transcriptional target and demonstrated 
the existence of a crosstalk between p53 and the IFN pathway both in tumor suppression and antiviral 
defense [4]. An increasing body of work indicates that in fact, p53 crosstalk takes place both at the 
level of IFN production and IFN signaling. These findings indicate that p53, through direct 
transcriptional upregulation of several target genes, influences the type I IFN pathway that further 
suggests an important role for p53 in innate immunity. Here, we have summarized a list of genes that 
are transcriptional targets of both type I IFN and p53 and the possible implications of this crosstalk in 
antiviral immunity. 
4.1. IRF9 
IRF9 is, along with STAT1 and STAT2 [43], an integral part of the ISGF3 complex, with a critical 
role in the activation of antiviral genes, as demonstrated by the severely immuno-compromised status 
of Irf9-/- mice [44]. The ISGF3 complex regulates the expression of antiviral genes harboring ISREs in 
their promoters, including p53 [4]. However, IRF9 is also a p53 transcriptional target. We have 
recently shown that p53 induces the transcriptional upregulation of IRF9, which contributes to enhance 
the IFN signaling pathway leading to upregulation of ISRE-dependent genes such as IRF7, retinoic 
acid-inducible gene 1 (RIG-I) or MxA [6]. Importantly, and probably due to IRF9-dependent 
activation of IRF7, p53 also contributed to IFN production in cells infected with viruses such as Sendai 
(SeV), (Cantell strain) [6]. This link between p53 activity and production of IFN by infected cells has 
been also described during HIV infection, suggesting that this effect is not dependent on the virus type 
[45]. Consistent with an important role of p53 at enforcing the type I IFN signaling pathway, mice that 
conserve wt p53 were more protected from SeV infection than their p53-/- counterparts [6]. Similar to 
our results showing upregulation of IRF9 by p53 at transcriptional level, Shen and colleagues reported 
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that upregulation of p53 induced in response to influenza virus infection resulted also in the 
transactivation of IRF9 [46]. Finally, an upregulation of IFN signaling upon Hepatitis C virus (HCV) 
infection mediated by direct p53-IRF9 protein interaction has been also suggested [47]. Further 
research is required to determine whether these cellular responses are dependent on the kinetics of 
infection and/or the multiplicity of infection (MOI) employed in such experiments. The recent findings 
by Shen and colleagues indicating that p53 levels are upregulated upon infection with influenza A 
virus, leading to IRF9 and Bax upregulation [46], are consistent with previous studies that 
demonstrated that p53 is important for influenza-induced apoptosis, and thus, cells retaining wt p53 
have an enhanced apoptotic response to influenza A infection, which results in impaired viral 
replication [7]. These findings indicate that p53 activity contributes to both the enhancement of the 
type I IFN through IRF9 upregulation as well as virus-induced apoptosis in response to influenza 
infection. Furthermore, treatment of cancer cells harboring wt p53 with Ribavirin induced mammalian 
target of rapamycin (mTOR)-dependent activation of p53 that resulted in IRF9 transcriptional 
upregulation and enhancement of IFN signaling [48]. These studies indicate that p53 directly regulates 
IRF9 activity and provides a new link between the type I IFN pathway and p53, not only with 
implications in antiviral defense but also in tumor suppression.  
4.2. TLR3  
The first member of the TLR protein family was a Drosophila protein implicated in dorsoventral 
patterning during embryonic development [49]. Further studies indicated that the intracellular domain 
of Drosophila Toll showed striking similarities to the intracellular domain of the mammalian 
interleukin-1 (IL-1) receptor [50]. To date different human homologous of Drosophila Toll have been 
identified and shown to induce activation of several pro-inflammatory cytokines upon pathogen 
exposure including type I IFNs, TNF-and IL-8 [51]. TLRs are essential components of innate 
immunity due to their ability to sense pathogen-associated molecular patterns (PAMPs). Thus, TLRs 
along with other cellular pathogen sensors such as RIG-I or the NOD-like receptor (NLRs) family of 
proteins are considered pattern recognition receptors (PRRs) [52]. TLRs are well conserved from 
mammals to invertebrates underscoring their importance in innate immunity. In mammals, TLRs are 
composed presumably by 13 family members [53]. Among TLRs, TLR3, TLR7 and TLR9 play a 
major role in the recognition of virus infection due to their ability to sense double-stranded RNA 
(dsRNA), single stranded RNA (ssRNA) and CpG DNA motifs respectively [53], which are main 
subproducts of viral replication [54]. TLR3 is expressed in most cell types even though it might play a 
major role in recognition of dsRNA by conventional DCs, where it is expressed in cellular endosomes 
as opposed to fibroblasts in which it is expressed in the cell surface [55]. Upon recognition of dsRNA, 
TLR3 induces IFN production as well as IL-8, RANTES, and TNF-, leading toDC maturation which 
enhances their ability to present virus-derived antigens to naïve T cells by exposure of such antigens 
by class I and II histocompatibility complex (MHC-I and MHC-II) [56]. Therefore, TLR3 plays a 
major role at the interface between innate and adaptive immunity.  
A recent paper by Taura et al. indicated that TLR3 is a direct p53 downstream target gene [57]. 
Interestingly, the authors found not only a functional p53 binding site in the TLR3 promoter, but also 
they showed that TLR3-dependent up-regulation of IL-8 in response to dsRNA, is dependent to a great 
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extent on p53 in the p53 wt HCT116 human colon cancer cell line [57]. Moreover, TLR3 stimulation 
with synthetic dsRNA (poly I:C) in wt p53 HCT116 cells induced phosphorylation of the TLR3 
downstream target IRF3, a key event for the transactivation of the IFN-promoter, whereas IRF3 
phosphorylation was severely impaired in p53-/- cells [57]. In agreement with the author’s findings, 
unpublished results from our group indicate that cells lacking p53 are in fact, severely impaired in their 
ability to activate the IFN-promoter. A still open question is whether p53 affects the function of 
conventional DCs, which express high levels of TLR3. If so, such findings would imply that p53 
functions are important not only for innate antiviral immunity, but also to trigger adaptive immunity. 
Indeed, recent findings indicating that the type I IFN response is important for DC activation and 
antigen presentation [58,59] suggest that this may be actually the case. Moreover, this could also 
explain why p53-/- mice are more sensitive to some viral infections [4-6]. Further research is required 
to evaluate the possible role of p53 in the interface between innate and adaptive immunity as well as 
other possible cross-talks between p53 and the TLR family.   
4.3. IRF5  
IRF family members have been identified as transcription factors that act to prevent different types 
of cell stress, including viral infection and DNA damage [60]. In fact, the first IRF member 
discovered, IRF1, was previously shown to cooperate with p53 in the induction of apoptosis in cells 
undergoing DNA damage, as well as in the induction of cell cycle arrest through p21 [61]. Three 
members of the IRF family of proteins seem to play a major role as direct activators of the type I IFN 
response upon viral infection, IRF3, IRF7 and IRF5 [60,62]. These proteins are phosphorylated and 
translocated to the nucleus upon recognition of viral PAMPs by TLRs where they form part of a 
multimeric protein complex containing not only the IRFs, but also ATF-2/c-Jun, and NFkappaB, 
which leads to transactivation of the IFN-promoter, namely the type I IFN enhanceosome [63].  
IRF5 directly interacts with the TLR adaptor protein MyD88 and regulates TLR-dependent 
expression of pro-inflammatory cytokines such as IL-6 and IL-12 [64]. Interestingly, as opposed to 
IRF3 and IRF7, IRF5 activity over the type I IFN promoters seems to be to some extent virus-specific. 
IRF5 activity is upregulated in cells infected with NDV rather than in SeV infected cells [64]. These 
findings could indicate that IRF5 activity is restricted to viruses that are sensed by TLRs, and not to 
viruses preferentially recognized by the RIG-I signaling pathway, which seems to be the case of SeV 
[65]. Another unique feature of IRF5, as opposed to IRF3 and IRF7, is that its expression seems to be 
restricted to certain types of tissues. Constitutive expression of IRF5 can be detected primarily in 
lymphoid tissues and peripheral blood leukocytes (PBLs), and low levels of IRF5 can be found in 
skeletal muscle and prostate [66]. In agreement with the idea that IRF5 function is tissue restricted, 
MEFs from Irf5-/- mice did not show any defects in their ability to produce type I IFN when infected 
in vitro with VSV or herpes simplex virus-1 (HSV-1) but these mice were more susceptible to VSV 
and HSV-1-induced disease in vivo [67].  
IRF5 was identified as a direct p53 target gene by Mori and colleagues [68]. In this study the 
authors noticed an increase in IRF5 levels in cancer cell lines retaining wt p53 exposed to DNA 
damaging agents, and confirmed that p53 was able to bind to and transactivate the IRF5 promoter [68]. 
More recent studies by Yanai and colleagues indicate that, in comparison with IRF1 that cooperates 
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with p53 in both the induction of cell cycle arrest and apoptosis in response to DNA damage [61], 
IRF5 cooperates with p53 only in the induction of apoptosis in response to DNA damage but not in 
cell cycle arrest [67]. Even though both IRF5 and p53 seem to play an important role in innate 
immunity, it is currently unknown whether these two proteins cooperate in the induction of type I IFNs 
and/or antiviral genes.  
4.4. ISG15 
ISG15 is an ubiquitin homolog that regulates the function of multiple IFN-inducible genes upon 
activation of the type I IFN pathway [69]. Discovered more than two decades ago, its function as an 
ubiquitin-like protein modifier (a process that has been termed ISGylation) it’s just starting to be 
understood [69,70]. ISG15-dependent ISGylated proteins include important antiviral proteins such as 
PKR, RIG-I, or antiviral effector proteins such as MxA [71]. ISGylation usually drives protein 
activation since, as opposed to ubiquitylation; ISGylation does not promote protein degradation [69]. 
Thus, ISG15 impedes virus-dependent degradation of IRF3, prompting IFN-transactivation [72]. 
However, the specific mechanisms by which ISG15 promotes the activation of its target genes are in 
most of the cases largely unknown [69].  
The importance of ISG15 in the antiviral immune response is underscored by the fact that is one of 
the earliest IFN-induced genes [73]. Moreover, ISG15 has been shown to participate in specific 
aspects of antiviral immunity such as inhibition of EBOV budding and HIV assembly [74,75] and 
ISGylation by ISG15 has been also shown to be inhibited by influenza B non structural protein 1 
(NS1) [76].  
ISG15 was identified as a p53 direct target gene by Hummer and colleagues in 2001 [77]. The 
authors reported the presence of a functional p53 binding site adjacent to the core ISRE site of ISG15 
[77]. Intriguingly, this paper suggests that p53 promotes ISG15 upregulation after dsRNA stimulation 
rather than in response to IFN treatment or virus infection [77]. In view of the recent findings that link 
p53 and TLR3, it is tempting to speculate that the observed effects on ISG15 could be mediated 
through p53-dependent upregulation of TLR3 activity. Further investigations are required to decipher 
whether ISG15 may participate in the p53-dependent antiviral response and whether p53 may induce a 
different panel of genes in response to virus infection or dsRNA treatment.  
5. p53 as a target of viral antagonism 
Upon virus infection, IFN and the tumor suppressor p53 are employed by host cells as components 
of their antiviral defense mechanisms. Thus, viruses need to tightly oppose these antiviral surveillance 
mechanisms of the host. Viruses have evolved elaborate mechanisms to subvert p53-mediated host 
innate immune responses. Either p53 itself or cellular factors involved in its downstream activities are 
inactivated by various viral proteins either by releasing cells from cell-cycle checkpoints or by 
protecting cells from p53-dependent apoptosis [78-80]. The number of viruses that have been shown to 
interfere with p53 activity has increased during the last years. Simian virus 40 (SV40) large T antigen 
[78,81]; Epstein Barr virus (EBV) BZLF1 [82] and EBV EBNA3C [83]; Kaposi’s sarcoma associated 
herpesvirus (KSHV) LANA, LANA2 and ORF K8 [84-86]; the Human herpesvirus 6 (HHV6) ORF1 
[87], all interact with p53 and inhibit its activity. Adenovirus E1B-55K and E4-ORF6 proteins, human 
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papillomavirus (HPV) E6, EBV EBNA-5, KSHV vIRF4 and the vaccinia virus (VV) B1R kinase, all 
induce the degradation of p53 [88-93]. Other proteins such as Adenovirus E1A or HPV E7 stabilize 
p53 but inhibit its transcriptional activity [94-98]. KSHV vIRF1 interacts with the ATM kinase to 
block its activity, thereby reducing p53 phosphorylation at the serine 15 residue and increasing p53 
ubiquitylation [99,100]. EBNA-5 and polyoma virus target and inhibit critical ARF-mediated signals 
for p53 activation [101,102]. Other example such as the hepatitis B virus (HBV) X protein has been 
shown to interact with p53 and inhibits its functional activity in multiple ways [103].  
As mentioned earlier, the number of viruses that has been demonstrated to control apoptosis 
induced by a p53-dependent mechanism has increased in the latest years, however not all the viruses 
induce p53 downregulation or block apoptosis induced by p53-dependent pathways. Some studies 
have demonstrated how some viruses induce an increase in p53 levels or activation of p53-regulated 
pathways. Thus, p53 activation by EBV LMP1, cytomegalovirus (CMV) IE84 or IE72, RSV fusion 
protein F or HIV-1 [104-107] and both upregulation and activation of p53 by KSHV viral cyclin [108] 
have been reported. 
6. Summary 
p53 is a tumor suppressor gene which is found mutated or absent in more than 50% of human 
cancers [109]. In fact, due to the ability of p53 to respond in many ways to DNA damaging insults, this 
protein has been called ‘the guardian of the genome’ [110]. However, p53 is also present and 
functional in organisms whose life span precludes them from undergoing cancer-related diseases such 
as flies and worms [111,112]. Moreover, a recent body of work indicates that besides ‘classic’ p53 
inducers such as DNA damage and oncogene expression, its function can be also promoted by 
hypoxia, nutrient deprivation and viral infection [4,113,114]. These findings, and the recently 
identified functions of p53 in both virus-induced apoptosis and upregulation of the type I IFN 
response, are summarized in Figure 1, and suggest, that p53 may act as a virus induced cellular stress 
sensor. The role of p53 in antiviral immunity may help to explain to some extent why this protein is so 
highly conserved in evolution.  
Figure 1. Schematic of the activators and effectors of p53-dependent response in antiviral 
immunity. 
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